CHMP5

Across TCGA pan-cancer cohorts, CHMP5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CHMP5 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CHMP5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CHMP5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where CHMP5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.722	0.503	.012	10	view →
LSCC	DFS	Median	All	0.909	0.964	.011	10	view →
LUAD	DFS	Quartile	III,IV	0.854	0.328	.020	7	view →
PDAC	DFS	Quartile	II,III,IV	0.536	0.337	.009	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CHMP5–HNSC (DFS)

Open the HNSC breakdown →